TrialBlood advances2024

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.

Inhye E Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.